Trastuzumab Subcutaneous 21 days - Metastatic Breast Cancer. NCCP National SACT Regimen. HSE.

Regulatory approval published by the Health Service Executive.

Citation

Trastuzumab Subcutaneous 21 days - Metastatic Breast Cancer, 2021, version number 4, NCCP National SACT Regimen, NCCP, viewed 26/03/2026, https://healthservice.hse.ie/documents/6694/272_v4_Trastuzumab_SC_21days_MBC.pdf

View API

Regulatory approvals

Approved indications from this document for cancer drugs containing at least one biomarker.

Indication Statements
HER2 positive metastatic breast cancer (MBC) as monotherapy for the treatment of those patients who have received at least two chemotherapy regimens for their metastatic disease. Prior chemotherapy must have included at least an anthracycline and a taxane unless patients are unsuitable for these treatments. Hormone receptor positive patients must also have failed hormonal therapy, unless patients are unsuitable for these treatments. 2
HER2 positive metastatic breast cancer (MBC) in combination with PACLitaxel for the treatment of those patients who have not received chemotherapy for their metastatic disease and for whom an anthracycline is not suitable. 2
HER2 positive metastatic breast cancer (MBC) in combination with DOCEtaxel for the treatment of those patients who have not received chemotherapy for their metastatic disease. 2
HER2 positive metastatic breast cancer (MBC) in combination with an aromatase inhibitor for the treatment of postmenopausal patients with hormone-receptor positive MBC, not previously treated with trastuzumab. 6

Therapeutic response

Precision oncology relationships for therapeutic response derived from this document.

Organizations Biomarkers Cancer types Therapies
HSE (1) HER2-positive Invasive Breast Carcinoma Trastuzumab
HSE (1) HER2-positive Invasive Breast Carcinoma Docetaxel, Trastuzumab
HSE (1) ERBB2 amplification Invasive Breast Carcinoma Docetaxel, Trastuzumab
HSE (1) HER2-positive Invasive Breast Carcinoma Paclitaxel, Trastuzumab
HSE (1) ER positive, HER2-positive, PR positive Invasive Breast Carcinoma Anastrozole, Trastuzumab
HSE (1) ERBB2 amplification Invasive Breast Carcinoma Trastuzumab
HSE (1) ERBB2 amplification Invasive Breast Carcinoma Paclitaxel, Trastuzumab
HSE (1) ER positive, HER2-positive Invasive Breast Carcinoma Anastrozole, Trastuzumab
HSE (1) ER positive, ERBB2 amplification, PR positive Invasive Breast Carcinoma Anastrozole, Trastuzumab
HSE (1) ER positive, ERBB2 amplification Invasive Breast Carcinoma Anastrozole, Trastuzumab
HSE (1) ERBB2 amplification, PR positive Invasive Breast Carcinoma Anastrozole, Trastuzumab
HSE (1) HER2-positive, PR positive Invasive Breast Carcinoma Anastrozole, Trastuzumab